MECFA Blog

News & Articles

Award granted to Neem Biotech to develop antimicrobial intervention for chronic lung infections

Neem Biotech, a Wales based R&D pharmaceutical biotech working in the field of novel antimicrobial drug development, is pleased to announce that it has been granted a Venture & Innovation Award from the UK Cystic Fibrosis Trust to expand its cystic fibrosis programme. Neem are working on a novel approach to antimicrobial resistance, which involves preventing the formation of and disrupting mature biofilms that are produced by bacteria such as Pseudomonas aeruginosa and Staphylococcus aureus. In lung biofilm communities, bacteria are both protected against antibiotics and the host immune system. Elements within the biofilm also impact upon the level of hydration of the lungs in cystic fibrosi

Understanding How Bacteria ‘Talk’ Could Hold Key for New CF Treatments, Study Suggests

New research provides insights into how bacteria “talk” to each other in lung infections, which could provide strategies to block these signals and ease bacterial virulence in patients with cystic fibrosis (CF). The study, “Spatial determinants of quorum signaling in a Pseudomonas aeruginosainfection model,” was published in the journal Proceedings of the National Academy of Sciences. Quorum sensing is a process through which bacteria send and receive molecules to regulate gene levels in response to changes in cell density. The process may lead to altered virulence or the ability to establish an infection. But little is known about quorum sensing or bacterial growth during infection. “Much o

The 2019 European Cystic Fibrosis Conference to be held in Liverpool

ACC Liverpool will be the venue for the European Cystic Fibrosis Conference, to be held in the city for the first time. ACC Liverpool will host the 42nd European Cystic Fibrosis Conference in June 2019. The major international medical conference will attract more than 3,000 scientific and clinical professionals from around the world. The European Cystic Fibrosis Society is an international community of scientific and clinical professionals who work to promote high-quality research, education and care. Professor of child health at the University of Liverpool and Alder Hey Children’s Hospital's Kevin Southern, helped bring the event to Liverpool. Southern said: "Liverpool is world-renowned for

#ECFS2018 – Multiple Sclerosis Therapy Boosts Antibiotic’s Ability to Kill Resistant P. aeruginosa S

Combining the approved multiple sclerosis treatment glatiramer acetate with the antibiotic tobramycin improved its ability to kill antibiotic-resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis (CF) patients, new data show. These results were shared in the presentation “The repurposed multiple sclerosis drug, glatiramer acetate, is an antibiotic resistance breaker in Pseudomonas aeruginosastrains from cystic fibrosis patients,” given by Ronan A. Murphy with Imperial College London at the recent 41st European Cystic Fibrosis Society (ECFS) Conference held in Belgrade, Serbia. The study was funded by the U.K.’s Cystic Fibrosis Trust. Glatiramer acetate, manufactured and m

#ECFS2018 – 3 Scientists Win 2018 ‘Young Investigators Awards’ for Innovative CF Research

The European Cystic Fibrosis Society presented three scientists — one Portuguese, one Mexican, and one German — with the organization’s 2018 “Young Investigators Awards” on June 9, the last day of its 41st European Cystic Fibrosis Conference (ECFS) in Belgrade, Serbia. The winners are Iris Silva, Samuel Lara Reyna, and Mirjam Stahl. Each received a grant of €750 (about $884), and a 2018 ECFS membership subscription. The annual contest is open to researchers younger than 35 who submit their abstracts for review by the scientific committee of the ECFS. Susan Madge , PhD, of London’s Royal Brompton Hospital, also received this year’s ECFS Award for making a significant contribution to the under

#ECFS2018 – AB-PA01, with Antibiotics, Shows Promise in Treating Drug-resistant Lung Infections in C

AmpliPhi Biosciences’ investigative therapy AB-PA01, in combination with antibiotics, shows significant potential to treat multi-drug resistant Pseudomonas aeruginosa infection in cystic fibrosis (CF), according to the case report of a CF patient with recurrent pneumonia and pulmonary exacerbations. These positive early results further support the development of the treatment against P. aeruginosa bacteria in larger and controlled clinical trials. The case study was discussed at the 41st European Cystic Fibrosis Society (ECFS) Conference, held June 6-9 in Belgrade, Serbia, in a poster presentation titled “Bacteriophage treatment of multidrug-resistant Pseudomonas aeruginosa pneumonia in a cy

PTI-808

PTI-808 is an experimental therapy being developed by Proteostasis Therapeutics to treat the most common type of cystic fibrosis (CF) caused by the mutation F508 delta, a class 2 or protein-processing mutation. The potential treatment is currently in Phase 1 clinical trials, in both healthy volunteers and patients, to assess its safety and tolerability. How PTI-808 works Cystic fibrosis is a heritable disorder caused by mutations in the CFTR gene, which encodes for an ion transport protein that controls the salt and fluid balance in cells. The CFTR protein is a membrane protein that provides a tube or channel that directs ions in and out of the cell. Mutations in the CFTR gene result in the

#ECFS2018 — Hard-to-Treat Infections May Not Impact Survival of CF Patients After Lung Transplant, S

One-year survival after a lung transplant of cystic fibrosis (CF) patients chronically infected with antibiotic-resistant bacteria is similar to those without infections, according to a retrospective analysis of data from the International Society of Heart and Lung Transplantation (ISHLT) Thoracic Transplant Registry. Results of the study were shared today in a presentation, titled “Mortality outcomes related to multi-drug resistant organisms in cystic fibrosis lung transplant recipients: an International Society of Heart and Lung Transplantation (ISHLT) thoracic transplant Registry study,” at the 2018 European Cystic fibrosis Conference (ECFS), taking place through June 9 in Belgrade, Serbi

Scientists work to dissolve the NETs that worsen TBI damage

Immune cells that are first responders to a traumatic brain injury appear to also contribute to the secondary damage that can occur even days later, scientists say. The NETs—or neutrophil extracellular traps -these immune cells cast at the site of a TBI can become scaffolds for clots, and the scientists have evidence that dissolving NETs can reduce swelling and improve blood flow and recovery. A drug already used clinically for cystic fibrosis appears to do just that. "Neutrophils are kind of the foot soldiers of the immune system. They are constantly circulating around so when you get a cut or any kind of injury, they are the first ones on the scene," says Dr. Krishnan Dhandapani, neuroscie

Spyryx SPX-101 Phase 2 HOPE-1 Trial Shows Improvement in Lung Function in Patients with Cystic Fibro

DURHAM, N.C., June 6, 2018 /PRNewswire/ -- Today Spyryx shared positive data for the first cohort of the SPX-101 Phase 2 clinical trial HOPE-1 (Hydration for Optimal Pulmonary Effectiveness), which showed that treatment with SPX-101 in patients with cystic fibrosis (CF) resulted in a meaningful benefit for lung function via a novel method for modulation of ENaC. Notably, the inhaled peptide therapeutic can be used in all patients regardless of their CF mutation. On Friday June 8 at the European Cystic Fibrosis Society in Belgrade, Serbia, Isabelle Fajac, M.D., Ph.D., Principal Investigator, Vice President and President Elect of the European Cystic Fibrosis Society and Professor of Physiology

Cystic Fibrosis Medications: What You Need to Know

Cystic fibrosis is a life-threatening, genetic disease that affects patients’ ability to breathe and is marked by persistent lung infections. While it currently has no cure, a number of treatments, therapeutics, and supplements exist to help cystic fibrosis patients maintain their health and well-being. These include medications approved for the disease, but treatment plans are unique and tailored to each patient’s specific health characteristics and needs. Cystic fibrosis medications range from CFTR modulators and enzyme supplements, to mucolytics, antibiotics, and vitamins. NOTE: The following is not necessarily an exhaustive list of cystic fibrosis medications and treatments. Cystic Fibro

Way Found to Use Antimicrobial Peptides, Part of Immune System, to Treat Bacterial Lung and Wound In

Antimicrobial peptides administered as tiny nanoparticles show promise in treating bacterial infections without risking making the bacteria more resistant to treatment — as can happen with antibiotics, an EU-supported study reports. Unlike antibiotics, antimicrobial peptides or AMPs are part of the innate immune system, naturally occurring molecules that work as the body’s first-line of defense against threats like bacteria. But past attempts to use antimicrobial peptides failed to mostly due to their lack of stability, leading them to degrade quickly. Now, researchers found that using nanoparticles as a vehicle to deliver these small molecules directly to an infection site significantly imp

#ECRD2018 – Genome Editing Might Be ‘Cure’ for Rare Diseases But Ethical Guidelines Needed, Panel Sa

Should scientists have the right to edit the genes of future generations to eliminate hundreds, if not thousands, of potential rare diseases? Or should researchers restrict their use of genome editing to somatic cells, so that they don’t pass changes on to the next generation? What about stem-cell research, three-parent in vitrofertilization (IVF), and experimenting on animals? These and other ethical issues are at the center of society’s current debate on genome editing and its implications for patients with rare diseases — most of which have no treatments or cures. “Somatic genome editing is being used in basic research, using human cells and modifying them for loads of different reasons,”

Vast Therapeutics’ Therapy Candidate BIOC51 Fares Well in Mouse Studies

Vast Therapeutics, formerly known as Novoclem Therapeutics, recently announced that the company’s first controlled nitric oxide (NO) release powder-based therapy candidate, BIOC51, can substantially reduce the bacterial load of nontuberculous mycobacteria (NTM) in the lungs of animal models of cystic fibrosis. Vast Therapeutics is a preclinical stage pharmaceutical company exploring the power of NO in a synthetic powder-based form for the treatment of severe respiratory infections in patients with CF and other respiratory diseases. BIOC51 is its proprietary water-soluble, NO-releasing biopolymer that has been modified with a specific type of NO to facilitate spontaneous and controlled NO rel

Study finds antioxidant-enriched vitamin reduces respiratory illnesses in patients with CF

Children's Hospital Colorado and the University of Colorado School of Medicine lead a multicenter clinical trial that identifies benefits of a specially formulated antioxidant supplement Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxidant-enriched multivitamin may decrease respiratory illnesses in people with cystic fibrosis (CF). The study, which was recently published online in the American Journal of Respiratory and Critical Care Medicine, looked at the effects of a 'cocktail' of multiple antioxidants on inflammation and health outcomes in patients with CF. Inflammatio

Featured Posts
Recent Posts
Archive
Search By Tags

Support Zahra's run for Palestine CF patients.

  • Facebook Clean
  • Twitter Clean
  • Instagram - Grey Circle
  • YouTube - Grey Circle
  • LinkedIn Clean